Key terms
About SONN
Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its pipeline focuses on cytokines, a class of cell signaling peptides that, among other important functions, serve as potent immunomodulatory agents. The company was founded by Pankaj Mohan and John K. Cini in 2011 and is headquartered in Princeton, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SONN news
Mar 11
8:43am ET
Sonnet BioTherapeutics announces safety data from Phase 1b/2a trial of SON-080
Mar 11
7:42am ET
Sonnet BioTherapeutics Advances SON-080 into Phase 2 Trials
Feb 15
7:59am ET
Sonnet BioTherapeutics price target lowered to $30 from $75 at Chardan
Feb 15
7:56am ET
Buy Recommendation for Sonnet BioTherapeutics: Clinical Progress and Strong Financial Position
Feb 14
7:41am ET
Sonnet BioTherapeutics reports Q1 EPS (31c) vs. ($17.62) last year
Jan 07
5:47am ET
BTIG Reaffirms Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)
Jan 02
9:49am ET
Sonnet BioTherapeutics Holdings (SONN) Gets a Buy from BTIG
Dec 31
5:26am ET
BTIG Keeps Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)
Dec 22
4:34pm ET
Sonnet BioTherapeutics files $100M mixed securities shelf
Dec 21
8:18am ET
Sonnet BioTherapeutics announces publication of preclinical data on SON-1210
Dec 15
2:59am ET
Buy Rating Affirmed for Sonnet BioTherapeutics Amid Promising Oncology Trials and Financial Fortitude
SONN Financials
Key terms
Ad Feedback
SONN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SONN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
